Physician
Pain Clinic Management Group, PLLC
Pain Clinic Management Group, PLLC was paid $3.06M by Medicaid between Mar 2019 and Dec 2024, across 42 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 54% of everything it billed.
33Billing provider infoPAIN CLINIC MANAGEMENT GROUP, PLLC
STERLING HEIGHTS, MI 48310
STERLING HEIGHTS, MI 48310
33aNPI1225302821assigned 02/28/2012
33bProvider typeInterventional Pain Medicine Physician
28Total paid$3.06M
24GClaims48,248
24DCodes billed42
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Michigan
Rank by total paid#3 of 23
Median peer was paid$312K
This provider vs. median9.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,499 | $76K | |
| 2020 | 5,726 | $311K | |
| 2021 | 12,205 | $764K | |
| 2022 | 11,847 | $779K | |
| 2023 | 9,269 | $605K | |
| 2024incomplete | 7,702 | $524K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 54% | 25,464 | 24,188 | $1.66M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 17% | 3,935 | 3,914 | $507K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.7% | 6,124 | 5,890 | $266K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.4% | 4,859 | 4,824 | $166K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.7% | 1,657 | 1,655 | $143K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.6% | 739 | 733 | $109K |
| 99443 | 2.5% | 1,024 | 989 | $77K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 318 | 317 | $29K |
| 62323 | <1% | 518 | 469 | $29K | |
| 64493 | <1% | 376 | 316 | $26K | |
| 64494 | <1% | 357 | 294 | $14K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 109 | 103 | $8K |
30 more codes
| 64635 | <1% | 47 | $6K | |
| 72275 | <1% | 234 | $4K | |
| 64483 | <1% | 45 | $3K | |
| 64495 | <1% | 77 | $3K | |
| 64636 | <1% | 46 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 14 | $2K |
| 62321 | <1% | 19 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $839.54 |
| 99406 | <1% | 129 | $738.17 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 116 | $700.73 |
| 20611 | <1% | 12 | $664.51 | |
| 64484 | <1% | 14 | $430.94 | |
| 80305 | <1% | 40 | $200.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 153 | $173.34 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 109 | $85.31 |
| G0030 | Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user | <1% | 12 | $0.02 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 86 | $0.00 |
| J3490 | Unclassified drugs | 0% | 72 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 80 | $0.00 |
| 1006F | 0% | 14 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 108 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 45 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 32 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 655 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 421 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 54 | $0.00 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 16 | $0.00 |
| 4040F | 0% | 14 | $0.00 | |
| 1124F | 0% | 27 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 64 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETER, JASON (MEMBER)